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High prevalence of albuminuria 
amongst people who inject drugs:  
A cross-sectional study
c. R. McGowan1,2 ✉, T. Wright1, D. nitsch3, D. Lewer4, R. Brathwaite5, J. Scott6, V. Hope7, 
D. ciccarone8, J. Dunn9, J. Gillmore10, A. Story4,11 & M. Harris1
Albuminuria is a key biomarker for cardiovascular disease and chronic kidney disease. our study aimed 
to describe the prevalence of albuminuria amongst people who inject drugs in London and to test 
any potential associations with demographic characteristics, past diagnoses, and drug preparation 
and administration practices. We carried out a cross-sectional survey amongst people who use drugs 
in London. the main outcome measure was any albuminuria including both microalbuminuria and 
macroalbuminuria. three-hundred and sixteen samples were tested by local laboratory services. our 
study initially employed point-of-care testing methods but this resulted in a high number of false 
positives. Our findings suggest the prevalence of albuminuria amongst PWID is twice that of the general 
population at 19% (95%CI 15.3–24.0%). Risk factors associated with albuminuria were HIV (aOR 4.11 
[95% CI 1.37–12.38]); followed by overuse of acidifier for dissolving brown heroin prior to injection (aOR 
2.10 [95% CI 1.04–4.22]). Albuminuria is high amongst people who inject drugs compared to the general 
population suggesting the presence of increased cardiovascular and renal pathologies. This is the first 
study to demonstrate an association with acidifier overuse. Dehydration may be common amongst this 
population and may affect the diagnostic accuracy of point-of-care testing for albuminuria.
People who inject drugs (PWID) may be at risk of serious cardiovascular and kidney diseases, including AA 
amyloidosis, related to chronic inflammatory conditions and poor overall health. Certain drug injecting practices 
(e.g. subcutaneous injecting, reuse of injecting equipment) are associated with chronic or recurrent abscesses 
and other skin and soft tissue infections (SSTIs)1. Currently, there are few studies looking at early risk markers of 
cardiovascular disease and chronic kidney disease among PWID, though there is some evidence to suggest that 
PWID are at increased risk of developing end-stage renal disease2–5. Other injecting practices believed to precipi-
tate inflammation relate to the over-use of acidifiers used to dissolve brown heroin which is the predominant type 
of heroin available in Europe6. It is well established that chronic inflammation is associated with both cardiovas-
cular disease and chronic kidney disease7,8.
Albuminuria is one of the two biochemical markers used to identify the presence of both cardiovascular dis-
ease and chronic kidney disease9. The presence of albuminuria is a key risk marker for predicting progression to 
end-stage renal disease, and for identifying other serious sequelae including AA amyloidosis9. A person with ele-
vated albuminuria but with normal estimated glomerular filtration rate (eGFR) has the same cardiovascular risk 
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as a person with an low eGFR (<60) without albuminuria9,10. Albuminuria has been associated with additional 
microvascular pathologies (e.g. involving the skin, brain, lungs) which suggests that albuminuria may also be a 
marker of systemic microvascular disorder11. Albuminuria is associated with cardiovascular risk factors includ-
ing; overweight/obesity, diabetes, high blood pressure, and tobacco smoking10.
Population-level estimates reveal a high prevalence of albuminuria in the UK. A 2004 study among those aged 
40–79 years in Norfolk, UK estimated the prevalence of microalbuminuria as 11.2% (13.9% in women, 8.1% in 
men) and macroalbuminuria as 0.7% (0.7% in women, 0.8% in men)12. The 2009 and 2010 Health Surveys for 
England estimated that 8% of adults surveyed had abnormal levels of albumin in their urine (7.9% microalbu-
minuria, 0.5% macroalbuminuria)10.
This paper aims to describe the prevalence of albuminuria among PWID, and to inform the clinical use and 
interpretation of albuminuria testing amongst this population.
Methods
We undertook a cross-sectional survey, as part of the UK National Institute for Health Research-funded 
Care & Prevent study, aimed at assessing the evidence for AA amyloidosis amongst PWID13. We developed a 
computer-assisted questionnaire to identify patterns of drug use and potential risk factors for SSTIs and AA amy-
loidosis. The questionnaire was conducted with current or past PWID aged 18 years and over who were recruited 
in London at eight drug treatment services and a mobile health service working with homeless people (UCLH 
Find & Treat Service). Participants completed the questionnaire followed by a urine screen for albuminuria. 
Participants were asked questions relating to: demographics, injecting history, injection practices, HIV and hepa-
titis C virus (HCV) status, SSTI history, and other conditions associated with albuminuria. Potential confounders 
were age, sex, and tobacco smoking.
Urine was initially tested using laboratory urinalysis and/or point of care (POC) testing using CLINITEX 
Microalbumin Reagent Strip (Siemens Healthcare GmbH), however, the POC testing yielded a high number of 
false positives (See Text Box 1) and was abandoned in favour of laboratory urinalysis. Albumin levels between 2.8 
and 29.9 mg/mmol were considered abnormal (i.e. microalbuminuria), and ≥30 mg/mmol were deemed highly 
abnormal (i.e. macroalbuminuria). Participants with macroalbuminuria were referred to the University College 
London (UCL) National Amyloidosis Centre at Royal Free Hospital in North London for diagnostic assessment 
for AA amyloidosis.
Text Box 1. We initially used CLINITEK Microalbumin 2 Strips in a CLINITEK Status+ Analyser to 
determine the albumin-to-creatine ratio (ACR) of urine samples. CLINITEK Microalbumin 2 Strips were 
selected as they are specified for use with spontaneous urine samples and measure both albumin and cre-
atinine values, enhancing the specificity of results. Despite manufacturer guidelines and reviews assuring 
adequate specificity and sensitivity for POC testing, we found a discrepancy in 20 of the 45 samples that were 
also sent for laboratory testing. While POC results indicated albuminuria in 58% of cases (26 micro and 1 
macro), laboratory results for the same samples showed 13% with albuminuria (6 micro and 1 macro). (See 
Figure 1) Given this discrepancy we abandoned POC testing. We brought on an additional site with a labo-
ratory pathway, and developed a collaboration with the UCLH Find & Treat Service outreach team, enabling 
us to recruit through homeless hostels via their outreach team and to use their private laboratory pathway.
The discrepancy between POC samples and laboratory samples is likely due to the highly concentrated 
urines of many participants. Concentrated urine has a very high creatinine level, which would have exceeded 
the microalbumin strip cut-off point – thus creating a false positive. Highly concentrated urines were also 
observed on handling, indicating inadequate water consumption and possible dehydration in this population. 
Aside from the health implications of dehydration, our findings indicate that semi-quantitative POC testing 
should be avoided or used with extreme caution with this population.
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Figure 1. Discrepancy between CLINITEK and laboratory results for ACR.
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Survey data were collected in Open Data Kit (https://opendatakit.org/) and transferred into Stata 15 (StataCorp: 
College Station, TX) for analysis.
All participants were provided with study information sheets and gave written consent prior to answering the 
questionnaire and providing a sample for urinalysis. Participants were reimbursed for their time with a £10 gift 
voucher. All methods were carried out in accordance with the relevant guidelines and regulations. This study has 
been reported against the STROBE reporting checklist for observational studies14.
patient and public involvement. The survey was developed in collaboration with the Lambeth and 
Camden Drug User Forums. Members of the National Amyloidosis Centre Patient Network helped develop the 
participant information sheets. Groundswell, a local homelessness charity15, provided input to the study as well as 
peer support16,17 (See GRIPP2 Reporting Checklist Appendix 1).
Sample size. We aimed to collect urine samples from 400 participants based on feasibility (rates of service 
attendance) and an estimated 5% prevalence of proteinuria (95% CI, 3–7%).
Quantitative variables. The main outcomes of interest were any albuminuria; microalbuminuria (a bio-
marker for other health outcomes, such as cardiovascular disease) and macroalbuminuria (a biomarker for 
AA-amyloidosis). Exposures were chosen a priori as plausible factors in the causal chain and were based on the 
literature, our clinical experience, and our prior research involving PWID. Exposures include: injecting practices, 
location of injection sites, number of injection sites used, SSTI history, severity of past or current SSTI, housing 
status, overuse of acidifier (for dissolving drugs prior to injection), and self-reported lifetime diagnoses of health 
conditions (e.g. necrotising fasciitis, COPD, sepsis, endocarditis). Smoking status was added to the survey fol-
lowing commencement of data collection owing to the unexpectedly high prevalence of microalbuminuria, and 
is thus only available for 75% of the total sample, and 95% of the subsample of participants for whom we have 
laboratory results.
Statistical analysis. Associations between potential risk factors and albuminuria were tested using crude 
logistic regressions. Bivariate associations found to have a significance of ≤0.1 were introduced into the multi-
variate logistic model to examine independent associations with albuminuria. We used a 95% confidence interval 
for the calculation of population point estimates of albuminuria. We further estimated a ratio of the prevalence of 
albuminuria in our PWID sample to the prevalence in the general population using data from the Health Survey 
for England 2016, which included urinalysis. We fit a poisson regression model on the combined data with albu-
minuria as the dependent variable and drug injection as the independent variable, adjusting for age group and 
sex. We then additionally adjusted for smoking status (current, former, or non-smoker).
ethics Approval. The study was approved by the NHS Health Research Authority (218143), the NHS 
Research Ethics Committee (17/LO/0872), and the London School of Hygiene & Tropical Medicine Observational 
Research Ethics Committee (12021–1). Participants gave informed consent to participate in the study.
Results
Of the 455 participants who completed the survey, 442 consented to urinalysis. Three-hundred and sixteen lab-
oratory urinalyses were returned. The 139 samples not included in the analysis were either tested using the POC 
CLINITEX Microalbumin Reagent Strips only (e.g. for services with no laboratory pathway) or they were rejected 
N = 316 %
Age
<35 44 13.9
35–44 85 26.9
45–54 137 43.4
>54 50 15.8
Gender
Male 236 74.7
Female 80 25.3
Stability of housing in previous 12 months
Stable (own place, rented) 136 43
Unstable (other people’s places, street homeless, hostel dwelling) 180 57
Ever been street homeless 242 76.6
Ethnicity
White or White British 230 72.8
African, Caribbean or Black British 39 12.3
Asian or Asian British 7 2.2
Mixed ethnicity 21 6.7
Other 19 6
Table 1. Participant Characteristics.
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by the laboratory (e.g. the sample container was damaged). We compared the personal characteristics of those 
from whom we obtained a sample to those from whom we did not using the Mann–Whitney U test (for age) and 
Pearson χ-squared and found no significant difference between the two groups (See Appendix 2).
Descriptive data. The majority of the 316 participants were white (73%) and male (75%), both their mean 
and median age was 46 years old (IQR 39–52). The average age at first injection drug use was 24 years (See 
Table 1). Of the 316 participants, 169 (54%) reported a diagnosis of HCV, 77 (24%) deep vein thrombosis (DVT), 
45 (14%) chronic obstructive pulmonary disease (COPD), 27 (9%) kidney disease, and seven (2%) necrotising 
fasciitis. Seventeen (5%) participants reported receiving an HIV diagnosis (See Table 2).
The majority of participants reported having a history of street homelessness (n = 242, 77%), with 57% 
(n = 180) currently living in unstable accommodation. The majority reported a typical injecting practice which 
included injecting one or more times per day (n = 227, 72%), and/or injection into the femoral vein (lifetime: 
n = 136, 43%, past 12 months: n = 62, 32%) (See Table 3). One-hundred and thirteen (39%) reported over-use 
of acidifier (defined as more than half a sachet of citric acid or vitamin C6) when preparing a £10 bag of heroin. 
Three hundred participants provided data on smoking status; 272 (91%) reported current or past smoking.
outcome data. Of the 316 urinalysis results, sixty-one (19.3% [95% CI 15.3–24.0]) were positive for albu-
minuria with ≥2.8 mg/mmol albumin/creatinine ratio. Of these, 52 (16% [95% CI 12.8–21.0]) were classified as 
having microalbuminuria, and nine (3% [95% CI 1.5–5.4]) had macroalbuminuria. Men and women differed 
slightly but not significantly: 21.2% (95% CI 16.4–26.9) of men and 15% (95% CI 8.6–24.8) of women were 
found to have albuminuria. The prevalence of albuminuria generally increased with age: 13.6% (95% CI 6.1–27.7) 
in participants aged ≤35, and 21.4% (95% CI 16.1–27.9) in those aged ≥45, however this was not significant 
(p > 0.05). The nine participants with macroalbuminuria were referred to the UCL National Amyloidosis Centre 
and were offered Groundswell peer support (four declined to attend, three attended, and two died before their 
appointment).
Main results. In a series of crude analyses the following associations were found with albuminuria (See 
Table 4 for associations): acidifier overuse (OR 1.77, p = 0.061), COPD (OR 2.15, p = 0.033), HCV (OR 1.86, 
p = 0.037), DVT (OR 1.69, p = 0.090), HIV (OR 3.18, p = 0.025), and injecting in three body sites (OR 2.49 
p = 0.079). There was no significant association between SSTIs (OR 0.87, p = 0.643) or groin injecting (OR 1.36, 
p = 0.282).
Based on these associations we performed logistic regression using listwise deletion of observations with 
missing smoking status and adjusted for a priori confounders (i.e. age, gender, and current smoking). We found 
higher odds of having albuminuria amongst those who: reported using more than half a sachet of acidifier per 
£10 of heroin (aOR 1.71 [95% CI 0.90–3.25]); had been previously diagnosed with COPD (aOR 1.85 [95% CI 
0.84–4.06]), HCV (aOR 1.72 [95% CI 0.93–3.20]), HIV (aOR 3.16 [95% CI 1.06–9.41]), and injecting in three 
body sites (aOR 2.08 [95% CI 0.71–6.06]).
Further adjustment for other covariates suggested that the risk factor with the largest association with albu-
minuria was HIV (aOR 4.11 [95% CI 1.37–12.38]) followed by over-use of acidifier in injection preparation (aOR 
2.10 [95% CI 1.04–4.22]).
In order to determine the age-adjusted prevalence ratio we compared our sample to the Health Survey for 
England data for 2016. Accounting for smoking status and stratified by age, we excluded the youngest (<25) and 
oldest (65+) age groups as they included small numbers of observations. The adjusted prevalence ratio suggests 
that albuminuria is twice as prevalent (1.97 [95% CI 1.49–2.60]) in our population compared to the general pop-
ulation in England.
N = 316 %
Hepatitis C 169 53.5
Deep Vein Thrombosis (DVT) 77 24.4
Arthritis 71 22.5
Hypertension 65 20.6
Sepsis 63 19.9
Chronic Obstructive Pulmonary Disease (COPD) 45 14.2
Hepatitis B 40 12.7
Liver cirrhosis 39 12.3
Kidney disease 27 8.5
Diabetes 18 5.7
Bone or joint infection 18 5.7
HIV 17 5.4
Endocarditis 14 4.4
Tuberculosis 13 4.1
Necrotising fasciitis 7 2.2
Lymphangitis 4 1.3
Table 2. Participant Lifetime Morbidities.
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Discussion
Statement of principal findings. This study sought to determine the prevalence of albuminuria amongst 
PWID in London. Previous studies have estimated that albuminuria in the general adult population in the UK is 
less than 10%12,18,19. Our findings suggest prevalence amongst PWID is twice that at 19% (15.3–24.0%). However, 
the age distribution in our sample differs markedly from that of the general adult population18. Adjusting for 
current smoking the prevalence ratio decreased to 1.65 (95% CI 1.17–2.31), suggesting that about one-third of 
the increased prevalence relates to smoking. Within our sample of PWID, overuse of acidifier and HIV were 
important predictors of albuminuria.
HIV is known to be associated with proteinuric renal lesions20. Additionally, we hypothesise that persistent 
overuse of acidifier in injection solution is precipitating venous sclerosis (owing to endothelial stress), thus com-
plicating venous access and resulting in multiple venous injection attempts (and possible accidental subcutaneous 
injecting) and/or transition to intentional subcutaneous injecting21. Subcutaneous injecting introduces substances 
and/or bacteria directly into tissues which, in turn, causes persistent localised inflammation1. Alternatively, we 
cannot rule out the possibility that over-use of acidifier is directly causing local or systemic inflammation6. Chronic 
inflammation is strongly associated with cardiovascular and renal disease of which albuminuria is a biomarker9.
These data suggest that PWID are a high-risk group to develop cardiovascular and renal complications. A 
recent study of mortality among people who use heroin in South London found 2.8 times the risk of cardiovascu-
lar mortality compared to the general population22. If the associations (as observed in the general UK population) 
between albuminuria and future risk of cardiovascular disease are also true for PWID, one would expect the 
stroke risk in this population to be increased by 90% relative to a person with no albuminuria23, whilst the abso-
lute risk of cardiovascular mortality increases by about 30% for a doubling of albuminuria24.
Strengths and weaknesses of the study. Initially, urine sample testing was carried out using a POC 
testing machine; however, false positives were identified following confirmatory laboratory testing We believe this 
to be a result of high levels of dehydration amongst PWID. Our prevalence estimate may have been improved by 
testing twice (as per NICE guidelines); however, this would have been difficult given our study population9. The 
Health Survey for England albuminuria data were collected based on the same protocol used for the present study 
(i.e. a single sample) therefore increasing its comparability with our study population18.
The absence of a significant association between SSTIs and albuminuria was surprising as we anticipated SSTIs 
would be a key factor in activating the inflammatory cascade. It is possible that our participants underreported 
past SSTIs or that our sample was underpowered to draw out this association. Our study may also have been 
underpowered to detect other meaningful predictor variables. Fnally, we cannot rule out the possibility that HIV 
and excessive use of acidifier may be contributing to a systemic microvascular disorder.
Unanswered questions and future research. Future studies should investigate long-term outcomes of 
PWID realted to cardiovascular and renal risk, though we appreciate the challenges of following up a difficult 
to capture population. Future trials should investigate whether cardiovascular and renal disease may be delayed 
by blood pressure lowering therapy or a poly-pill (i.e. a pill containing a combination of several medications) in 
n %
Ever injected psychoactive drugs for non-medical purposes† 316 100
Ever injected in arms 301 95.3
Ever injected in hands 234 74.1
Ever injected in legs 193 61.1
Ever injected in feet 177 56
Ever injected in groin 136 43
Ever injected in neck 119 37.7
Ever injected in other 46 14.6
Injected in the last 12 months‡ 190 60.1
Heroin alone 136 71.6
Heroin and crack 134 70.5
Crack alone 57 30
Powder cocaine 22 11.6
Amphetamine 16 8.4
Ketamine 10 5.3
Other 6 3.2
Prescription diamorphine 12 6.3
Methadone 6 3.2
Mephedrone 6 3.2
Heroin with amphetamines 9 4.7
Steroids or other performance enhancing drugs 2 1.1
Table 3. Injection Practices. †In order from most commonly identified as ‘main bodysite injected’, to least. ‡In 
order from most commonly identified as ‘main drug injected’, to least.
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Variable
Albuminuria (micro/
macro) Crude Adjusted*
Multiple 
adjusted**
NO (%) YES (%) OR (95% CI) AOR (95% CI) AOR (95% CI)
Reuse needles and syringes
No 79 (81%) 18 (19%) 1 — —
Yes 176 (80%) 43 (20%) 1.07 (0.58–1.98) — —
Reuse filters
No 109 (80%) 28 (20%) 1 — —
Yes 140 (82%) 30 (18%) 0.83 (0.47–1.48) — —
Injecting frequency per week
Once 30 (77%) 9 (23%) 1 — —
2–3 times a week 28 (85%) 5 (15%) 0.60 (0.18–2.00) — —
4–6 times a week 13 (76%) 4 (24%) 1.03 (0.27–3.95) — —
Once a day 28 (80%) 7 (20%) 0.83 (0.27–2.54) — —
2–3 times a day 99 (84%) 19 (16%) 0.64 (0.26–1.56) — —
≥ Four times a day 57 (77%) 17 (23%) 0.99 (0.40–2.50) — —
Current smoker
No 25 (89%) 3 (11%) 1 — —
Yes 221 (81%) 51 (19%) 1.92 (0.56–6.63) — —
Ever inject in hands
No 69 (84%) 13 (16%) 1 — —
Yes 186 (79%) 48 (21%) 1.37 (0.70–2.69) — —
Ever inject in arms
No 13 (87%) 2 (13%) 1 — —
Yes 242 (80%) 59 (20%) 1.58 (0.35–7.23) — —
Ever inject in feet
No 115 (83%) 24 (17%) 1 — —
Yes 140 (79%) 37 (21%) 1.27 (0.72–2.24) — —
Ever inject in legs
No 102 (83%) 21 (17%) 1 — —
Yes 153 (79%) 40 (21%) 1.27 (0.71–2.28) — —
Ever inject in groin
No 149 (83%) 31 (17%) 1 — —
Yes 106 (78%) 30 (22%) 1.36 (0.78–2.38) — —
Number of sites ever injected
One 56 (86%) 9 (14%) 1 1 1
Two 35 (83%) 7 (17%) 1.24 (0.42–3.65) 1.16 (0.40–3.35) 0.73 (0.18–2.91)
Three 25 (71%) 10 (29%) 2.49 (0.90–6.89) 2.08 (0.71–6.06) 3.01 (0.98–9.22)
Four or more 139 (80%) 35 (20%) 1.57 (0.71–3.48) 1.36 (0.61–3.00) 1.53 (0.64–3.64)
Ever had SSTI
No 82 (80%) 20 (20%) 1 — —
Yes 173 (81%) 41 (19%) 0.97 (0.54–1.76) — —
Severity of infection
Mild/moderate 85 (80%) 21 (20%) 1 — —
Severe 65 (80%) 16 (20%) 1.00 (0.48–2.06) — —
Unstable housing
No 113 (83%) 23 (17%) 1 — —
Yes 142 (79%) 38 (21%) 1.31 (0.74–2.33) — —
Acidifier overuse
No 152 (85%) 27 (15%) 1 1 1
Yes 86 (76%) 27 (24%) 1.77 (0.97–3.21) 1.71 (0.90–3.25) 2.10 (1.04–4.22)
Diagnoses of health condition
HIV
   No 245 (82%) 54 (18%) 1 1 1
   Yes 10 (59%) 7 (41%) 3.18 (1.16–8.73) 3.16 (1.06–9.41) 4.11 (1.37–12.38)
HCV
   No 126 (86%) 21 (14%) 1 1 1
   Yes 129 (76%) 40 (24%) 1.86 (1.04, 3.33) 1.72 (0.93–3.20) 2.07 (0.99–4.31)
Continued
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those with albuminuria. In addition, studies could explore the reversibility of albuminuria through risk reduction 
and/or entry into substance use treatment (e.g. opioid agonist therapy). We encourage evaluations of the efficacy 
and cost-effectiveness of albuminuria screening amongst PWID.
conclusion
Albuminuria is twice as prevalent among PWID compared to the general population and may identify those 
with high cardiovascular and renal risk. Clinicians, such as general practitioners, should be aware of the risk and 
consider albuminuria testing of PWID. Finally, dehydration may be common amongst PWID and may affect the 
diagnostic accuracy of POC testing for albuminuria. We encourage careful interpretation of albuminuria tests 
among this population.
Variable
Albuminuria (micro/
macro) Crude Adjusted*
Multiple 
adjusted**
NO (%) YES (%) OR (95% CI) AOR (95% CI) AOR (95% CI)
DVT
   No 198 (83%) 41 (17%) 1 1 —
   Yes 57 (74%) 20 (26%) 1.69 (0.92–3.12) 1.37 (0.70, 2.67) —
COPD
   No 224 (83%) 47 (17%) 1 1 1
   Yes 31 (69%) 14 (31%) 2.15 (1.06–4.36) 1.85 (0.84–4.06) 1.97 (0.86–4.50)
Table 4. Associations Between Albuminuria and Risk Factors. *Adjusted for age, gender, and smoking. **Stepwise 
model adjusted for: age, gender, smoking, number of injection sites, over-use of acidifier, HIV, HCV, COPD.
APPENDIX 1: GRIPP2 Short Form
Section and topic Item
Reported on 
page No
1: Aim Report the aim of PPI in the study 3
2: Methods Provide a clear description of the methods used for PPI in the study 3
3: Study results Outcomes—Report the results of PPI in the study, including both positive and negative outcomes 5
4: Discussion and 
conclusions
Outcomes—Comment on the extent to which PPI influenced the 
study overall. Describe positive and negative effects. n/a
5: Reflections/critical 
perspective
Comment critically on the study, reflecting on the things that went 
well and those that did not, so others can learn from this experience n/a
APPENDIX 2:  Table comparing demographics for those with and without an ACR 
result
ACR result No ACR result
Pearson’s chi 
squared
Mann 
Whitney U
N = 316 % N = 139 % χ2 (df) P value z P value
Age 1.3 0.194
<35 44 13.9 21 15.1
35–44 85 26.9 45 32.4
45–54 137 43.4 57 41
>55 50 15.8 16 11.5
Gender 0.04 (1) 0.846
Male 236 74.7 105 75.5
Female 80 25.3 34 24.5
Stability of housing in previous 12 months 0.07 (1) 0.794
Stable (own place, rented) 136 43 58 41.7
Unstable (other people’s places, street homeless, 
hostel dwelling) 180 57 81 58.3
Ever been street homeless 242 76.6 113 81.3 1.25 (1) 0.263
Ethnicity 4.00 (4) 0.407
White or White British 230 72.8 106 76.3
African, Caribbean or Black British 39 12.3 11 7.9
Asian or Asian British 7 2.2 5 3.6
Mixed ethnicity 21 6.7 6 4.3
Other 19 6 11 7.9
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